On July 23, Molina Healthcare fell 6.69% in after-hours trading, trading at $207.0/share, with turnover of approximately $2.6 million. The decline followed the release of the company's second-quarter earnings report, which revealed a sharp deterioration in profitability despite a modest beat on consensus estimates.

Molina reported Q2 adjusted EPS of $1.51, surpassing the analyst consensus of $1.39 by 8.63%, while revenue of $10.874 billion edged past the $10.794 billion estimate. However, the quarterly profit represented a 72.45% collapse from $5.48 per share in the year-ago period. Additionally, the company's full-year guidance explicitly flagged that legacy MAPD (Medicare Advantage Prescription Drug) products are underperforming expectations, projecting a $1.00 per share earnings drag from that segment. The combination of severely compressed margins and ongoing Medicare Advantage headwinds overshadowed the top- and bottom-line beats, triggering the post-earnings selloff.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)